Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.
Conditions
Interventions
Nivolumab
Locations
16
United States
Uc Davis Medical Center
Sacramento, California, United States
Univ. Of Colorado Health
Colorado Springs, Colorado, United States
Denver Health Medical Center
Denver, Colorado, United States
University Of Florida
Gainesville, Florida, United States
Pulmonary And Critical Care Of Atlanta
Atlanta, Georgia, United States
Osf Saint Francis Medical Center
Peoria, Illinois, United States
Start Date
December 7, 2016
Primary Completion Date
January 5, 2018
Completion Date
January 5, 2018
Last Updated
April 23, 2019
NCT04955210
NCT06143137
NCT02473263
NCT02664753
NCT02777606
NCT02041663
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions